NASDAQ:ANL 延时15分钟

成交量

Yang Lu: Yang Lu is the founder of Adlai Nortye Ltd., where he currently serves as the Chairman & Chief Executive Officer. He founded the company in 2018. Mr. Lu previously worked as the Managing Director at Sinopep-Allsino Bio Pharmaceutical Co., Ltd. from 2004 to 2006. Mr. Lu holds an MBA from China Europe International Business School, which he obtained in 2012. He also completed his undergraduate studies at Xiamen University in 2002.

Ming Lun Tse: Ming Lun Tse currently works at Tian Ge Interactive Holdings Ltd., as Independent Non-Executive Director from 2022, Adlai Nortye Ltd., as Independent Non-Executive Director from 2021, and Association of Chartered Certified Accountants (Hong Kong), as Member from 2005. Mr. Tse also formerly worked at Next Horizon Co. Ltd., as Senior Manager-Corporate Planning & Development from 2007 to 2009. Mr. Tse received his undergraduate degree in 2002 from The University of Hong Kong.

Lars E. Birgerson: Lars E. Birgerson is President & Chief Executive Officer at Adlai Nortye USA, Inc. since 2018. He is Director at Trialbee AB since 2016. He is Director at Adlai Nortye Ltd. since 2023. Formerly, he was Vice President-Medical Affairs at Genentech, Inc. He was Vice President, Head-Global & US Medical Affairs at Roche Pharma (Schweiz) AG. He was President at Hangzhou Adlai Nortye Biopharma Co. Ltd. He was Chief Medical Officer at Adlai Nortye Ltd. Education includes doctorates conferred in 1977 and 1990 from the University of Uppsala.

Shao Rong Liu: Shao Rong Liu is an Independent Director at Adlai Nortye Ltd. since 2023. Previously, he served as an Independent Director at CoCreation Grass Co., Ltd. from 2018 to 2024. Mr. Liu holds an MBA from China Europe International Business School, conferred in 2012.

Roger A. Sawhney: Roger A. Sawhney is currently Director at SIRPant Immunotherapeutics, Inc., Arbutus Biopharma Corp., Adlai Nortye Ltd., and Independent Director at Actuate Therapeutics, Inc., all starting in 2024 or 2025. Dr. Sawhney is also Chief Business Officer at Neuvogen, Inc. Former roles include Director at Alimera Sciences, Inc. in 2023; Managing Director & Partner at The Boston Consulting Group, Inc. from 1996 to 2009; Director at KKR Group Co., Inc. from 2018 to 2020; Independent Director at Arcellx, Inc.; Director at New York Institute of Technology; SVP-Corporate Strategy & Business Development at ContextMedia Health LLC from 2017 to 2018; Senior VP & Head-Global Corporate Strategy at Novartis AG from 2009 to 2012; Chief Financial Officer at Stratus Therapeutics, Inc. from 2022 to 2023; Partner at Bain & Co., Inc. from 2012 to 2017; Chief Business Officer at Omega Therapeutics, Inc. in 2022; and Chief Financial Officer at LB Pharmaceuticals, Inc. Education includes undergraduate studies at Stanford University and a doctorate from Harvard Medical School.

阿诺医药